HSP
Heat shock proteins
HSP (Heat shock proteins) are a group of proteins induced by heat shock, the most prominent members of this group are a class of functionally related proteins involved in the folding and unfolding of other proteins. HSP expression is increased when cells are exposed to elevated temperatures or other stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans. Heat shock proteins appear to serve a significant cardiovascular role. Hsp90, Hsp84, Hsp70, Hsp27, Hsp20 and alpha B crystallin all have been reported as having roles in the cardiovasculature.
HSP Isoform Specific Products
All Product Categories
-
HSP Inhibitors
(312)
View all products
-
HSP Agonists
(2)
View all products
-
HSP Antagonists
(6)
View all products
-
HSP Activators
(83)
View all products
-
HSP Modulators
(6)
View all products
-
HSP Inducers
(6)
View all products
-
HSP Degraders
(8)
View all products
-
HSP Pre-designed Set
(1)
View all products
-
HSP Controls
(2)
View all products
-
HSP Ligands
(8)
View all products
-
HSP Related Products (482)
Related Products (482)
-
Antibodies (46)
-
HSP Isoform Comparison
-
Hsp90-IN-40
0 ImagesCat. No.: HY-171755CAS No.: 2169278-81-1Hsp90-IN-40 (Compound 15b) is a heat shock protein 90 (Hsp90) C-terminal inhibitor. Hsp90-IN-40 exhibits antiproliferative activity against SKBr3 and MCF-7 breast cancer cells (IC50 of 2.57 µM and 2.43 µM, respectively). Hsp90-IN-40 inhibits cancer cell growth by inhibiting the Hsp90 C-terminal function, leading to Hsp90-dependent protein degradation. Hsp90-IN-40 can be used in breast cancer research.
-
Hsp90-IN-47
0 ImagesCat. No.: HY-186076CAS No.: 958888-13-6Hsp90-IN-47 (Compound C15) is a Hsp90 inhibitor and antifungal agent, with an IC50 of 0.014 μM against Hsp90α. When combined with Fluconazole (HY-B0101), Hsp90-IN-47 exerts significant synergistic antifungal effects against fluconazole-resistant Candida albicans 0304103. Hsp90-IN-47 exhibits antitumor activity against acute myeloid leukemia and non-small cell lung cancer.
-
STA-1474
0 ImagesCat. No.: HY-13752CAS No.: 1118915-78-8STA-1474 is an orally active and highly selective HSP90 inhibitor, as well as a phosphate prodrug of the HSP90 inhibitor STA-9090 (HY-15205). STA-1474 disrupts the chaperone function of HSP90 and promotes the degradation of client proteins. STA-1474 inhibits the phosphorylation of Met, Akt and STAT3, thereby blocking related signaling pathways. STA-1474 induces apoptosis and inhibits proliferation of osteosarcoma cells, and triggers the up-regulation of HSP70 and HSP90. STA-1474 induces tumor regression and caspase-3 activation in mouse osteosarcoma xenograft models. STA-1474 can be used in the research of osteosarcoma.
-
(Rac)-Zearalanone-d6
0 ImagesCat. No.: HY-N6678SCAS No.: 1795020-90-4(Rac)-Zearalanone-d6 is the d6-labeled (Rac)-Zearalanone (HY-N6678A). (Rac)-Zearalanone is an ATP-competitive HSP90 inhibitor with an EC50 of 2.3 μM. (Rac)-Zearalanone interferes with the binding of ATP to HSP90, impairs the chaperone function of HSP90, and promotes the degradation of client proteins. (Rac)-Zearalanone reduces intracellular accumulation of Raf-1, induces cleavage of caspase-3, and promotes Her2 degradation in a dose-dependent manner by disrupting the Her2-HSP90 interaction. (Rac)-Zearalanone can be used in the research of small cell lung cancer and breast cancer.
-
Hsp90-IN-15
0 ImagesCat. No.: HY-150655CAS No.: 2252283-32-0Hsp90-IN-15 is an Hsp90 inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of Hsp90 in Hela cell.
-
Antiproliferative agent-72
0 ImagesCat. No.: HY-176538CAS No.: 1052646-54-4Antiproliferative agent-72 (Compound 10) is a Hsp90 inhibitor with a Kd of 11 nM. Antiproliferative agent-72 has antiproliferative activity with IC50s of 1.5 μM and 1.1 μM for HCT116 and NCI-N87 cells, respectively. Antiproliferative agent-72 can be used for cancers research.
-
Hsp90-Cdc37-IN-4
0 ImagesCat. No.: HY-174347CAS No.: 2758818-41-4Hsp90-Cdc37-IN-4, a Celastrol (HY-13067) derivative, inhibits the Hsp90-Cdc37 protein-protein interaction (PPI). Hsp90-Cdc37-IN-4 selectively inhibits casein kinase 2 (CK2), reducing phosphorylation of its substrate Cdc37 at Serine 13. Hsp90-Cdc37-IN-4 induces G0/G1 cell cycle arrest and triggers apoptosis via the mitochondrial pathway. Hsp90-Cdc37-IN-4 demonstrates potent anti-breast cancer activity.
-
Palmitic acid-d17
0 ImagesCat. No.: HY-N0830S14CAS No.: 81462-28-4Palmitic acid-d17 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
-
Hsp90-IN-38
0 ImagesCat. No.: HY-170895CAS No.: 3065556-04-6Hsp90-IN-38 (compound 20m) is a HSP90 (heat shock protein) inhibitor. Hsp90-IN-38 exhibits strong HSP90 binding affinity with a Kd of 87 nM. Hsp90-IN-38 inhibits ATPase with an IC50 of 0.13 μM. Hsp90-IN-38 inhibits HCT116, MCF-7, SKBr3, K562 and A549 cells with IC50s of 0.187, 0.072, 0.105, 0.403 and 031 μM, respectively.
-
Tamoxifen-13C6
0 ImagesCat. No.: HY-W778408CAS No.: 1346606-38-9Synonyms: ICI 47699-13C6; (Z)-Tamoxifen-13C6; trans-Tamoxifen-13C6Tamoxifen-13C6 (ICI 47699-13C6) is the 13C-labeled Tamoxifen (HY-13757A). Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen also can induce gene knockout of CreER transgenic mouse.
-
Metalnikowin I
0 ImagesCat. No.: HY-P11396CAS No.: 172430-37-4Synonyms: MetIMetalnikowin I (MetI) is a proline-rich antimicrobial peptide and DnaK inhibitor. Metalnikowin I can be derived from insects.
-
PU-20F
0 ImagesCat. No.: HY-121706CAS No.: 422508-29-0PU-20F is a Hsp90 inhibitor with an EC50 of 6.8 μM. PU-20F competes with Geldanamycin (HY-15230) for binding to Hsp90 and regulates the function of this molecular chaperone. PU-20F induces the degradation of oncogenic Her2 tyrosine kinase. PU-20F blocks the growth of breast cancer cells. PU-20F can be used in breast cancer-related research.
-
S1g-10
0 ImagesS1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells.
-
KUNB106
0 ImagesCat. No.: HY-178956CAS No.: 2393980-27-1KUNB106 is a selective Hsp90β inhibitor with KDs of 91 nM and 38 μM against Hsp90β and Hsp90α. KUNB106 exhibits antiproliferative activity against MDA-MB-231 cells, A549 and SKOV-3 cells. KUNB106 can be used for the study of triple negative breast cancer.
-
Hsp70TAC PD-1 Degrader-2
0 ImagesCat. No.: HY-182959Hsp70TAC PD-1 Degrader-2 is a PD-L1 Hsp70TAC (Hsp70-targeting Chimeras) degrader with Kd values of 0.36 μM. Hsp70TAC PD-1 Degrader-2 forms a ternary complex with Hsp70 and PD-L1 to drive PD-L1 degradation. Hsp70TAC PD-1 Degrader-2 induces degradation of mature membrane-bound PD-L1 in an Hsp70-dependent manner and via caveolin-mediated endocytosis and lysosomal trafficking. Hsp70TAC PD-1 Degrader-2 accumulates preferentially in tumor cells with elevated Hsp70 expression for tumor-selective PD-L1 degradation. Hsp70TAC PD-1 Degrader-2 can be used for the research of cancer, such as breast invasive carcinoma, glioblastoma multiforme, diffuse large b-cell lymphoma. (Pink: PD-1/PD-L1 ligand (HY-19745A); Blue: Hsp70 ligand (HY-182979); Black: linker (HY-182982)).
-
6BrCaQ-C10-TPP
0 ImagesCat. No.: HY-144831CAS No.: 3036044-73-96BrCaQ-C10-TPP is a potent mitochondrial heat shock protein TRAP1 inhibitor, with antiproliferative activity in various human cancer cells (IC50=0.008-0.30 μM). 6BrCaQ-C10-TPP can also induces mitochondrial membrane disturbance.
-
HSP70-IN-6
0 ImagesCat. No.: HY-163854CAS No.: 3048341-44-9HSP70-IN-6 (JL-15) is an inhibitor of Hsp70-Bim protein-protein interaction, with an IC50 value of 0.07 μM against Hsp70-Bim PPI, an IC50 of 4.89 μM and a Kd of 0.123 μM for BimBH3-stimulated Hsp70 ATPase activity. HSP70-IN-6 selectively blocks the binding of Hsp70-Bim without affecting the Hsp70-Bag3 interaction, and inhibits BimBH3-stimulated Hsp70 ATPase activity but has no impact on basal ATPase activity. HSP70-IN-6 induces apoptosis (apoptosis) in chronic myeloid leukemia cells in an Hsp70-Bim-dependent manner. HSP70-IN-6 can be used in research related to chronic myeloid leukemia.
-
PU3
0 ImagesCat. No.: HY-121881CAS No.: 352519-21-2PU3 is an Hsp90 inhibitor that competes with geldanamycin (GM) and others for the conserved ATP/ADP pocket of Hsp90. PU3 also induces degradation of proteins such as Her2 and inhibits breast cancer cell growth by causing retinoblastoma protein hypophosphorylation, G1 arrest, and cell differentiation. PU3 has the potential to be a cancer inhibitor..
